A Community-Centered Approach to CELMoD Education in Relapsed/Refractory Multiple Myeloma

A Community-Centered Approach to CELMoD Education in Relapsed/Refractory Multiple Myeloma is organized by Medical Learning Institute Inc (MLI).

Release Date: Aug 21, 2026
Expiration Date: Aug 20, 2027

Description:
This educational activity features 10 two-minute videos addressing key unmet needs in the management of relapsed/refractory multiple myeloma (RRMM), with a focus on cereblon E3 ligase modulators (CELMoDs). Topics include the role of cereblon in myeloma biology and IMiD resistance, CELMoD mechanism of action, strategies for overcoming resistance, and rational combinations with backbone agents; clinical evidence supporting novel iberdomide- and mezigdomide-containing regimens; evolving sequencing strategies with CELMoDs, CAR T-cell therapy, and bispecific antibodies; and practical approaches to mitigating adverse events associated with CELMoD-based combinations. Collectively, this video series is designed to provide clinicians with current, evidence-based guidance to support treatment selection, combination and sequencing decisions, and toxicity management for patients with RRMM.

Learning Objectives:
After completing this activity, the participant should be better able to:

• Describe the role of and mechanism of action of cereblon E3 ligase modulating drugs (CELMoDs) and how CELMoDs mechanistically differ from immunomodulatory drugs.
• Interpret emerging evidence for CELMoD-containing combinations to identify appropriate integration points across lines of RRMM therapy.
• Assess the potential of integrating CELMoDs within treatment paradigms and sequencing strategies with T-cell redirecting-therapies in patients with RRMM.